Mefenamic Acid

DRUG INFORMATION

  ADULT
    - After observing the response to initial therapy with mefenamic acid capsules, the
      dose and frequency should be adjusted to suit an individual patient's needs. 2.2
      For the Management of Mild to Moderate Pain The recommended dosage in adults and
      pediatric patients 14 years of age and older is 500 mg given orally as an initial
      dose followed by 250 mg every 6 hours as needed.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of mefenamic acid capsules have been established for
      management of mild to moderate pain in pediatric patients 14 years of age and
      older. The safety and effectiveness of mefenamic acid capsules have been
      established for treatment of primary dysmenorrhea in pediatric patients.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'pediatric use',
      retrieved 2026-08-29
    - After observing the response to initial therapy with mefenamic acid capsules, the
      dose and frequency should be adjusted to suit an individual patient's needs. 2.2
      For the Management of Mild to Moderate Pain The recommended dosage in adults and
      pediatric patients 14 years of age and older is 500 mg given orally as an initial
      dose followed by 250 mg every 6 hours as needed.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - ( 8.3 ) 8.1 Pregnancy Risk Summary Use of NSAIDs, including mefenamic acid, can
      cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction
      leading to oligohydramnios and, in some cases, neonatal renal impairment.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'use in specific
      populations', retrieved 2026-08-29
    - Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs at about 20 weeks
      gestation or later in pregnancy has been associated with cases of fetal renal
      dysfunction leading to oligohydramnios, and in some cases, neonatal renal
      impairment.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'use in specific
      populations', retrieved 2026-08-29
    - Oligohydramnios/Neonatal Renal Impairment: If an NSAID is necessary at about 20
      weeks gestation or later in pregnancy, limit the use to the lowest effective dose
      and shortest duration possible.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'use in specific
      populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - Discontinue if abnormal liver tests persist or worsen or if clinical signs and
      symptoms of liver disease develop.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'warnings and
      cautions', retrieved 2026-08-29
    - ( 5.5 ) Renal Toxicity : Monitor renal function in patients with renal or hepatic
      impairment, heart failure, dehydration, or hypovolemia.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'warnings and
      cautions', retrieved 2026-08-29
    - Additionally, patients with advanced liver disease and/or coagulopathy are at
      increased risk for GI bleeding.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'warnings and
      cautions', retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Use of NSAIDs, including mefenamic acid, can cause premature closure
      of the fetal ductus arteriosus and fetal renal dysfunction leading to
      oligohydramnios and, in some cases, neonatal renal impairment.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'pregnancy',
      retrieved 2026-08-29
    - Because of these risks, limit dose and duration of mefenamic acid capsules use
      between about 20 and 30 weeks of gestation, and avoid mefenamic acid capsules use
      at about 30 weeks of gestation and later in pregnancy (see Clinical
      Considerations, Data) .
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'pregnancy',
      retrieved 2026-08-29
    - Premature Closure of Fetal Ductus Arteriosus Use of NSAIDs, including mefenamic
      acid capsules, at about 30 weeks gestation or later in pregnancy increases the
      risk of premature closure of the fetal ductus arteriosus.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Infertility Females Based on the mechanism of action, the use of prostaglandin-
      mediated NSAIDs, including mefenamic acid may delay or prevent rupture of ovarian
      follicles, which has been associated with reversible infertility in some women.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'nursing
      mothers', retrieved 2026-08-29
    - Small studies in women treated with NSAIDs have also shown a reversible delay in
      ovulation.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'nursing
      mothers', retrieved 2026-08-29
    - Consider withdrawal of NSAIDs, including mefenamic acid, in women who have
      difficulties conceiving or who are undergoing investigation of infertility.
      Source: US FDA label for mefenamic acid (Mefenamic acid), section 'nursing
      mothers', retrieved 2026-08-29